1-7 of 7
Saul H. Rosenberg
Close
Sort by
Journal Articles

The Bcl-2 Family Protein Inhibitor, ABT-263, Promotes Apoptotic-Like Response in Isolated Platelets.

Chris Tse, PhD, Haichao Zhang, PhD, Jun Chen, PhD, Ryan M. Fryer, PhD, Richard Nelson, Paul Nimmer, Glenn A. Reinhart, PhD, Morey L. Smith, Stephen K. Tahir, PhD, Saul H. Rosenberg, PhD, Steven W. Elmore, PhD
Journal: Blood
Blood (2006) 108 (11): 1122.
https://doi.org/10.1182/blood.V108.11.1122.1122
Published: 2006
Journal Articles

The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice.

Alex R. Shoemaker, PhD, Michael J. Mitten, B.S., Jessica Adickes, B.S., Anatol Oleksijew, B.S., Haichao Zhang, Ph.D., Joy Bauch, B.S., Kennan Marsh, Ph.D., David J. Frost, Ph.D., David Madar, Ph.D., Christin Tse, Ph.D., Stephen W. Fesik, Ph.D., Saul H. Rosenberg, Ph.D., Steven W. Elmore, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 1107.
https://doi.org/10.1182/blood.V108.11.1107.1107
Published: 2006
Journal Articles

The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkin’s Lymphoma.

Alex R. Shoemaker, PhD, Michael J. Mitten, B.S., Anatol Oleksijew, B.S., Jacqeuline M. O’Connor, Baole Wang, M.D., Scott Ackler, Ph.D., Mary Joseph, Ph.D., Haichao Zhang, Ph.D., Paul Nimmer, B.S., Yu Xiao, B.S., Christin Tse, Ph.D., David J. Frost, Ph.D., Stephen W. Fesik, Ph.D., Saul H. Rosenberg, Ph.D., Steven W. Elmore, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 825.
https://doi.org/10.1182/blood.V108.11.825.825
Published: 2006
Journal Articles

Bcl-2 Family Protein Inhibitors Induce a Unique Thrombocytopenia In Vivo .

Steven W. Elmore, PhD, Joy Bauch, Ryan M. Fryer, PhD, Laurie Iciek, PhD, Kennan Marsh, PhD, Sherry J. Morgan, PhD, DVM, Richard Nelson, Glenn A. Reinhart, PhD, Morey L. Smith, Chris Tse, PhD, Saul H. Rosenberg, PhD
Journal: Blood
Blood (2006) 108 (11): 4236.
https://doi.org/10.1182/blood.V108.11.4236.4236
Published: 2006
Journal Articles

Inhibition of Bcl-2 Signaling at Nanomolar Concentrations by Small Molecule BH3 Inhibitor, ABT-737 as a Novel Therapeutic Strategy in Acute Myeloid Leukemia (AML).

Rooha Contractor, Marina Konopleva, M.D., Ph.D., Xingming Deng, M.D., Ph.D., David Harris, Peter Ruvolo, Ph.D., Zeev Estrov, M.D., W. Stratford May, M.D., Ph.D., Saul H. Rosenberg, Ph.D., Michael Andreeff, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 760.
https://doi.org/10.1182/blood.V104.11.760.760
Published: 2004
Journal Articles

Pro-Apoptotic Effects on CLL (Chronic Lymphocytic Leukemia) of ABT-737, a Novel Fully Synthetic Bcl-2/Bcl-XL Antagonist.

Shinichi Kitada, M.D., Ph.D., Edward Monosov, Ph.D., Sharon Chandler, Ph.D., Esther D. Avery, B.S., Thomas J. Kipps, M.D., Ph.D., Saul H. Rosenberg, Ph.D., John C. Reed, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 952.
https://doi.org/10.1182/blood.V104.11.952.952
Published: 2004
Journal Articles

Survivin does not inhibit caspase-3 activity

Damon P. Banks, Janet Plescia, Dario C. Altieri, Jun Chen, Saul H. Rosenberg, Haichao Zhang, Shi-Chung Ng
Journal: Blood
Blood (2000) 96 (12): 4002–4003.
https://doi.org/10.1182/blood.V96.12.4002
Published: 2000